AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03098420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine (TAP blocks)
Description: 20mL of 0% ropivacaine with 20mL of 0.5% ropivacaine
Study NCT03098420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study NCT03098420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Study NCT03098420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Study NCT03098420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Study NCT03098420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline 1ml
Description: 1.0 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
Study NCT03098420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline 0.5ml
Description: 0.5 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
Study NCT02236104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plethysmography opto electronic
Study NCT02236104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: respiratory parameters
Study NCT02222636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline,1 milliliter
Description: Normal saline,1 milliliter, 20 minutes before anaesthetic induction
Study NCT02222636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg.kg-1,1 milliliter
Description: Dexmedetomidine 1 μg.kg-1,1 milliliter,20 minutes before anesthesia induction
Study NCT02222636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2μg.kg-1,1 milliliter
Description: Dexmedetomidine 2μg.kg-1,1 milliliter,20 minutes before anesthesia induction
Study NCT02222636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anesthesia induction, 8% sevoflurane
Description: Inhalation induction with 8% sevoflurane
Study NCT02222636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia induction, 8% sevoflurane
Description: Inhalation induction with 8% sevoflurane
Study NCT02222636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anesthesia maintenance, 2%~3% sevoflurane,fentanyl
Description: 2%\~3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion
Study NCT02222636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia maintenance, 2%~3% sevoflurane,fentanyl
Description: 2%\~3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion
Study NCT04208776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: maximum tolerated dose of propranolol with initial dosage of 20mg once a day and uptitrating every 2nd day by 20 mg.
Study NCT04208776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: maximum tolerated dose of propranolol with initial dosage of 20mg once a day and uptitrating every 2nd day by 20 mg.
Study NCT04208776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: It will be started at 2.5mg TDS and will be uptitrated every 2nd day to a max of 10mg TDS to attain a MAP of atleast 70mm Hg and then uptitate the beta blocker simulataneously to attain the target heart rate
Study NCT03692260 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3D stent in Herbert screw insertion vs titanium plate
Description: benefit of 3d template in fracture gap
Study NCT01562509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation tools
Description: * Professionals receive audit \& feedback~* Patients (and clinicians) have access to a website with information tailored to patients with an NHL. This website gives insight into the logistic processes of each diagnostic tool and into the patients' personal care pathway.~* Standardization of diagnostic and evaluative request forms and reports for clinicians.~* Supporting material for standardizing the procedure for multidisciplinary meetings.
Study NCT01562509 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard intervention
Description: Standard intervention consists of audit\&feedback
Study NCT03768934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1X airtime incentive
Description: An incentive given in the form of airtime.
Study NCT03768934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2X airtime Incentive
Description: An incentive given in the form of airtime.
Study NCT03768934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lottery airtime incentive
Description: An incentive given in the form of airtime.
Study NCT01942694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D (Cholecalciferol)
Description: Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.
Study NCT01942694 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as one soft-gel pill daily by mouth
Study NCT02135796 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Study NCT00472576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0657
Description: Daily double-blind administration of the NR2B antagonist MK-0657 (4-8 mg/day)
Study NCT00472576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Daily double-blind administration of placebo
Study NCT03131570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Arms: Group 1 - Group 1 will receive Secukinumab at a dose of 300 mg with injections administered once weekly at baseline and at weeks 1, 2, 3, and 4 and then every 4 weeks for 6 months of period. In order to maintain the blind for the Group 2, Group 1 will receive placebo injections at weeks 13, 14, and 15. Group 1 will discontinue Secukinumab after 6 months of period being observed from week 25 to week 72 (48 weeks).
Study NCT03131570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo followed by Secukinumab
Description: Arms: Group 2 - Group 2 will receive placebo injections corresponding to the Group 1 regimen until week 8 in order to maintain a double-dummy design until week 12. From week 12, Group 2 will receive Secukinumab with injections administered once weekly at week 12 and at weeks 13, 14, 15, and 16 and then every 4 weeks for 3 months of period. Group 2 will discontinue Secukinumab after 6 months of period being observed from week 25 to week 72 (48 weeks).
Study NCT02288741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anthracycline/dexamethasone-based induction chemotherapy
Description: 4 cycles of anthracycline/dexamethasone-based chemotherapy
Study NCT02288741 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anthracycline/dexamethasone-based induction chemotherapy
Description: 4 cycles of anthracycline/dexamethasone-based chemotherapy
Study NCT02288741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone for control of symptoms
Description: 2 x 4 days of dexamethasone (day 1-4 and day 8-11: 40mg)
Study NCT02288741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor-reduction chemotherapy and stem cell mobilization
Description: Ifosfamide (day 1-3: 1.900mg/m² iv), epirubicin (day 1: 75 mg/m² iv), etoposide (day 1-3: 120 mg/m² iv) and G-CSF (day 5 until end of apheresis: 5µg/kg sc)
Study NCT02288741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tumor-reduction chemotherapy and stem cell mobilization
Description: Ifosfamide (day 1-3: 1.900mg/m² iv), epirubicin (day 1: 75 mg/m² iv), etoposide (day 1-3: 120 mg/m² iv) and G-CSF (day 5 until end of apheresis: 5µg/kg sc)
Study NCT02288741 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tumor-reduction chemotherapy and stem cell mobilization
Description: Ifosfamide (day 1-3: 1.900mg/m² iv), epirubicin (day 1: 75 mg/m² iv), etoposide (day 1-3: 120 mg/m² iv) and G-CSF (day 5 until end of apheresis: 5µg/kg sc)
Study NCT02288741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell apheresis
Description: stem cell apheresis in peripheral blood, sought amount of CD34-cells: 6 \* 10E6/kg
Study NCT02288741 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem cell apheresis
Description: stem cell apheresis in peripheral blood, sought amount of CD34-cells: 6 \* 10E6/kg
Study NCT02288741 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem cell apheresis
Description: stem cell apheresis in peripheral blood, sought amount of CD34-cells: 6 \* 10E6/kg
Study NCT02288741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tandem high-dose chemotherapy (melphalan)
Description: Two cycles of high-dose melphalan (day -3 and day -2: 70mg/m²)
Study NCT02288741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tandem high-dose chemotherapy (melphalan)
Description: Two cycles of high-dose melphalan (day -3 and day -2: 70mg/m²)
Study NCT02288741 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tandem high-dose chemotherapy (melphalan)
Description: Two cycles of high-dose melphalan (day -3 and day -2: 70mg/m²)
Study NCT02288741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood stem cell transplantation
Description: Two infusions of collected stem cells (day 0: 2\*10E6 CD34-cell/kg per transplantation)
Study NCT02288741 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous peripheral blood stem cell transplantation
Description: Two infusions of collected stem cells (day 0: 2\*10E6 CD34-cell/kg per transplantation)
Study NCT02288741 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autologous peripheral blood stem cell transplantation
Description: Two infusions of collected stem cells (day 0: 2\*10E6 CD34-cell/kg per transplantation)
Study NCT00497081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirtazapine
Description: mirtazapine 30 mg daily for 3 months
Study NCT00497081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 30 mg daily for 3 months
Study NCT03470389 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HVPG measurement
Description: Each patient's computed tomography, blood tests, Doppler ultrasound and HVPG measurement will be performed within 30 days and treatments that may affect HVPG value will be avoided during this period.
Study NCT03859934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin treatment
Study NCT03859934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo treatment
Study NCT00994500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT00994500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00999804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: 1000 mg of Lapatinib by mouth daily
Study NCT00999804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1000 mg of Lapatinib by mouth daily
Study NCT00999804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole, 2.5 mg by mouth daily (for hormone receptor positive participants only)
Study NCT00999804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole, 2.5 mg by mouth daily (for hormone receptor positive participants only)
Study NCT00994500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00994500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00999804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 6 mg/kg intravenously, every 3 weeks
Study NCT00999804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 6 mg/kg intravenously, every 3 weeks
Study NCT00071058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XR9576 (Tariquidar)
Study NCT02768857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensorimotor reeducation programs
Study NCT02768857 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sensorimotor reeducation programs
Study NCT00816348 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Omegaven
Description: Omegaven® will be initiated at a dose of 0.5 gram/kg/day and is infused over 24 hours for 1-2 days, and then advanced to 1 gram/kg/day. Omegaven® will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven® will continue until weaned from PN. Monotherapy with Omegaven® can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/kg/day, advancing to 1 gm/kg/day.
Study NCT00335036 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICD lead implant
Description: Randomization of ICD lead type at implant
Study NCT02485535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02485535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO
Study NCT02699034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ablation for typical atrial flutter
Study NCT02699034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vision-MR ablation catheter
Study NCT03726814 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EPC treatment group
Description: Brain injection EPC
Study NCT00718640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg per day will be administered orally on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-days cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).
Study NCT00718640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 milligram per meter\^2 (mg/m\^2), bolus intravenous injection will be administered on Days 1, 4, 8 and 11 of each 21-day cycle and up to 8 cycles.
Study NCT02700945 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reveal LINQ™ Insertable Cardiac Monitor
Description: The Medtronic Reveal LINQ™ ICM is a programmable device that continuously monitors a patient's ECG (electrocardiogram) and other physiological parameters. The device records cardiac information in response to automatically detected arrhythmias and patient activation.
Study NCT04300101 — intervention group
Intervention type: OTHER
Intervention: molecular characterization
Description: immunohistochemical determinations: Cell of Origin (COO) (according with Hans algorithm), evaluation of Cluster of Differentiation (CD) (CD20, CD5, CD10), Bcl6, Bcl2 (cut off>50%), MUM1/IRF4, c-myc (cut off>40%) and Ki67, FISH for c-myc and if rearranged for Bcl2 e Bcl6.~mRNA expression by Nanostring Single cell analysis Immune checkpoint expression Proteomic analysis Metabolic analysis
Study NCT00335036 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thin leads
Description: Thin (less than or equal to 7 French introducer) isodiametric ICD leads
Study NCT02466893 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Adapt/Standard Stent Retriever (SR) Group
Description: If the patient is randomized to mechanical thrombectomy, the groin puncture to initiate the procedure should occur within 1 hour of the clinical imaging used to determine trial candidacy. An introducer sheath will be placed in the femoral artery. Diagnostic angiography is initially performed via the transfemoral approach with catheterization of the carotid artery appropriate to the patient's presenting symptoms. Once thrombus in the appropriate vessel is identified, the thrombectomy procedure will be initiated.
Study NCT04706455 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sodium hyaluronate 0.1%
Description: Instillation of one drop sodium hyaluronate 0.1%
Study NCT01506141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idursulfase-IT
Description: Participants will receive Idursulfase-IT once monthly at the dose used in study HGT-HIT-045 via intrathecal drug delivery device (IDDD).
Study NCT01506141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elaprase
Description: Participants will receive weekly IV infusions of commercially available Elaprase.
Study NCT00565474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluvastatin
Description: Graft vasculopathy
Study NCT00565474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluvastatin
Description: Graft vasculopathy
Study NCT04706455 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sodium hyaluronate 0.3%
Description: Instillation of one drop sodium hyaluronate 0.3%
Study NCT01655485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient teaching
Description: The Social script application is an story book on the iPAD with photos and script explaining the steps of getting a medical image such as a CAT scan from the perspective of the child.
Study NCT04708561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech and language therapy
Description: The intervention focuses on understanding the thoughts of the characters. Twenty written stories will be used, which end with statements that can be interpreted literally, ironically, as a lie, a request or a faux-pas (maladroitness). At the end of each story, the participant should explain what the characters want to mean by their statement.~To help the participant in his understanding of the character's intention, he will be asked:~1) To mention as many intentions as possible that can be associated with the target statement presented out of context (eg: it's hot here that can be interpreted literally, ironically, as a lie or a request) and to imagine contexts in connection with interpretation; 2. Analyze the relevant elements of the context (environment, the relationship between the characters, knowledge of the characters); 3. To judge the probability of the possible interpretations (pt 1) by justifying using the elements of the context analyzed previously (pt 2).
Study NCT03829644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Horizon 627 Lumbar Brace, Aspen Medical Company, Oak Canyon, Irvine, CA 92618
Description: The brace is an FDA Class I device, one-size adjustable design to fit waists ranging from 24-70 inches. Participants will be instructed to wear the brace for six weeks. As this brace is semi-rigid, it does not prevent motion - only reduces motion in the lumbar areas. Our prior work and that of others have shown that this type of bracing does not reduce spinal function and is not associated with atrophy.
Study NCT01649778 — intervention group
Intervention type: DRUG
Intervention: Pazopanib
Description: Prospective Observational study collecting real world data on Pazopanib in patients with advanced or metastatic Renal Cell Carcinoma. Study is considered non-interventional, no drug will be provided. No study visits or procedures are mandated per protocol.
Study NCT04187781 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: external microphone
Description: External microphone is developed for direct transmission of speech into the hearing aids for better speech intelligibility, especially in noise.
Study NCT04263155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Body Project
Description: The Body Project is a 4-hour dissonance-based program designed to address body image concerns and prevent eating disorders. The curriculum consists of written, verbal, and behavioral exercises that provide participants with the opportunity to voluntarily and publicly critique the appearance ideal.
Study NCT00095888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV
Study NCT00095888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00095888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00095888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00120302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecrolimus cream 1 %
Study NCT00120302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching vehicle cream
Study NCT02317471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous gp96 vaccination
Description: Vaccination of gp96 derived from autologous tumor tissue. Treatment will be started between 3-6 weeks after the surgery.~gp96 of 25ug in 1mL normal saline s.c. on days 1 of each cycle, up to a maximum of 10 doses (1 cycle= 7 days). 200-400mg cyclophosphamide i.v. 1-3 days before each gp96 infusion.
Study NCT02317471 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin+S-1
Description: Treatment will be start at the 5th week after the surgery.~S-1: 40\~60mg bid，d1\~14 q3W; oxaliplatin:130mg/m2，iv drip for 2h，d1,q3W 6 cycles.